TTR and hereditary amyloidosis: Since their development, Tegsedi (antisense therapy), Onpattro (RNAi), Amvuttra (RNAi), and Wainua (antisense therapy) have all been licensed for the treatment of TTR-related hereditary amyloidosis [22].